Howard Chen, MD
Ophthalmology · Campbell
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 32
- 8 carriers
- Office
- 1
Offices
1 location · Retinal Diagnostic Center A Medical Corporation · 6 clinicians in this group
Plans that list them
32 plans · 8 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chen’s office at (408) 559-0666 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
32 of 32 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
| AARP Medicare Advantage from UHC CA-10 (HMO-POS) | UnitedHealthcare | Listed, may be out of date | Jun 10, 2026 |
California Medical Board record
Licence G83824 · Current
Licensed to practise in California · since 1997 · expires 2027-06-30 · New York University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Original Medicare doctor bills
$3,617,889
Medicare paid this office $3,617,889 for 1,339 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, faricimab-svoa, 0.1 mg | 316 | $2,253,640 | None |
| Injection, ranibizumab, 0.1 mg | 137 | $286,147 | None |
| Injection of drug into eye | 448 | $210,204 | $98 |
| Injection, avacincaptad pegol, 0.1 mg | 30 | $159,066 | None |
| Established patient complete exam of visual system | 930 | $137,530 | $104 |
See all 19 services
| Injection, faricimab-svoa, 0.1 mg | 316 | $2,253,640 | None |
| Injection, ranibizumab, 0.1 mg | 137 | $286,147 | None |
| Injection of drug into eye | 448 | $210,204 | $98 |
| Injection, avacincaptad pegol, 0.1 mg | 30 | $159,066 | None |
| Established patient complete exam of visual system | 930 | $137,530 | $104 |
| Injection, aflibercept, 1 mg | 29 | $136,235 | None |
| Established patient problem focused exam of visual system | 446 | $131,626 | $75 |
| Imaging of retina | 1,306 | $116,198 | $34 |
| New patient visit (45+ min) | 225 | $27,521 | $122 |
| 2d ultrasound scan of eye tissue and structures | 331 | $25,876 | $43 |
| Removal of membrane of retina with removal of internal limiting membrane of retina | 13 | $13,505 | $1,039 |
| Removal of eye fluid (vitreous) between lens and retina | 13 | $11,770 | $841 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 64 | $10,102 | $158 |
| Compounded drug, not otherwise classified | 35 | $8,770 | None |
| Photography of the retina | 140 | $6,188 | $30 |
| Photocoagulation treatment to prevent detachment of retina | 22 | $5,241 | $218 |
| New patient complete exam of visual system | 28 | $3,276 | $117 |
| Injection of drug or substance into membrane covering eyeball | 14 | $909 | $41 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 21 | $256 | None |
Procedures Medicare counted
| Cataract surgery | 1-10 | None |
Who their Medicare patients are
1,339 Original Medicare patients in 2024. Average age 79 · Under 65 3% · 85 and older 25% · Women 62% · Also on Medicaid 21% · Health risk score 1.29. Above the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 72% · Diabetes 29% · Chronic kidney disease 23% · Coronary heart disease 22% · Atrial fibrillation 19% · Heart failure 15% · Cancer 15% · Depression 14% · COPD 9% · Stroke 7% · Dementia 5%.
The office billed $12,670,528, Medicare allowed $4,615,580 and paid $3,617,889; for 97,012 services of 49 kinds; $2,847,594 of it was for drugs given in the office and $770,295 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,339 | 97,012 | 79 | 1.29 | $12,670,528 | $3,617,889 |
| 2023 | 1,322 | 40,703 | 78 | 1.28 | $10,481,515 | $2,839,477 |
| 2022 | 1,129 | 15,699 | 78 | 1.34 | $8,919,165 | $2,504,297 |
| 2021 | 1,054 | 12,652 | 78 | 1.31 | $7,876,465 | $2,367,457 |
| 2020 | 970 | 10,378 | 77 | 1.46 | $5,927,668 | $1,766,119 |
| 2019 | 1,367 | 12,671 | 77 | 1.50 | $6,535,496 | $1,855,695 |
| 2018 | 1,255 | 11,187 | 77 | 1.40 | $5,178,068 | $1,378,526 |
| 2017 | 1,167 | 10,248 | 77 | 1.43 | $4,155,701 | $1,003,572 |
| 2016 | 1,055 | 10,452 | 77 | 1.43 | $3,825,531 | $912,409 |
| 2015 | 1,046 | 9,778 | 77 | 1.36 | $3,649,638 | $842,938 |
| 2014 | 1,087 | 12,205 | 77 | 1.25 | $4,670,782 | $1,134,609 |
| 2013 | 1,190 | 12,217 | 77 | 1.33 | $5,479,971 | $1,473,707 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 17 services
| Injection, ranibizumab, 0.1 mg | 197 | $777,836 | None |
| Injection, faricimab-svoa, 0.1 mg | 145 | $744,044 | None |
| Injection, aflibercept, 1 mg | 109 | $538,523 | None |
| Injection of drug into eye | 404 | $198,032 | $101 |
| Established patient problem focused exam of visual system | 420 | $137,645 | $78 |
| Established patient complete exam of visual system | 928 | $134,302 | $105 |
| Imaging of retina | 1,278 | $112,867 | $35 |
| New patient visit (45+ min) | 263 | $35,033 | $133 |
| 2d ultrasound scan of eye tissue and structures | 305 | $23,181 | $44 |
| Compounded drug, not otherwise classified | 75 | $16,066 | None |
| Removal of membrane of retina with removal of internal limiting membrane of retina | 13 | $15,468 | $1,105 |
| Removal of eye fluid (vitreous) between lens and retina | 16 | $13,304 | $783 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 68 | $9,426 | $137 |
| Destruction of leaking blood vessels of retina using laser | 15 | $7,628 | $318 |
| Photography of the retina | 141 | $6,625 | $32 |
| Photocoagulation treatment to prevent detachment of retina | 19 | $4,556 | $228 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 20 | $208 | None |
2022: 15 services
| Injection, aflibercept, 1 mg | 139 | $910,722 | None |
| Injection, ranibizumab, 0.1 mg | 169 | $875,088 | None |
| Injection of drug into eye | 356 | $179,639 | $101 |
| Established patient problem focused exam of visual system | 343 | $118,563 | $77 |
| Established patient complete exam of visual system | 735 | $104,902 | $102 |
| Imaging of retina | 1,068 | $93,690 | $35 |
| Injection, faricimab-svoa, 0.1 mg | 14 | $46,552 | None |
| New patient visit (45+ min) | 259 | $32,464 | $125 |
| 2d ultrasound scan of eye tissue and structures | 283 | $22,113 | $43 |
| Compounded drug, not otherwise classified | 82 | $21,006 | None |
| Exam of retinal blood vessels using a special camera after injection of a dye | 73 | $8,717 | $119 |
| Photography of the retina | 171 | $6,970 | $30 |
| Destruction of leaking blood vessels of retina using laser | 12 | $6,913 | $314 |
| Photocoagulation treatment to prevent detachment of retina | 23 | $5,855 | $225 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 11 | $110 | None |
2021: 14 services
| Injection, aflibercept, 1 mg | 125 | $924,982 | None |
| Injection, ranibizumab, 0.1 mg | 116 | $783,307 | None |
| Injection of drug into eye | 308 | $171,458 | $105 |
| Established patient problem focused exam of visual system | 299 | $107,836 | $80 |
| Established patient complete exam of visual system | 646 | $102,723 | $108 |
| Imaging of retina | 915 | $89,460 | $37 |
| New patient visit (45+ min) | 252 | $34,075 | $135 |
| Compounded drug, not otherwise classified | 97 | $26,997 | None |
| 2d ultrasound scan of eye tissue and structures | 303 | $23,935 | $46 |
| Long return visit (40+ min) | 129 | $16,848 | $131 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 85 | $9,809 | $115 |
| Photography of the retina | 262 | $9,169 | $30 |
| Removal of eye fluid (vitreous) between lens and retina | 11 | $8,470 | $770 |
| Injection, bevacizumab, 10 mg | 11 | $853 | None |
2020: 17 services
| Injection, aflibercept, 1 mg | 104 | $653,268 | None |
| Injection, ranibizumab, 0.1 mg | 93 | $554,452 | None |
| Injection of drug into eye | 299 | $122,662 | $89 |
| Established patient complete exam of visual system | 623 | $103,355 | $105 |
| Established patient problem focused exam of visual system | 280 | $71,065 | $76 |
| Imaging of retina | 661 | $62,143 | $35 |
| Compounded drug, not otherwise classified | 130 | $33,355 | None |
| Photography of the retina | 521 | $24,940 | $40 |
| New patient visit (45+ min) | 175 | $21,631 | $124 |
| Long return visit (40+ min) | 176 | $19,766 | $112 |
| 2d ultrasound scan of eye tissue and structures | 287 | $19,287 | $48 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 75 | $7,668 | $100 |
| Photocoagulation treatment to prevent detachment of retina | 13 | $6,558 | $504 |
| Removal of eye fluid | 21 | $2,404 | $109 |
| Injection, bevacizumab, 10 mg | 21 | $1,702 | None |
| Injection of drug or substance into membrane covering eyeball | 13 | $728 | $49 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 20 | $109 | None |
2019: 25 services
| Injection, aflibercept, 1 mg | 113 | $687,762 | None |
| Injection, ranibizumab, 0.1 mg | 74 | $398,253 | None |
| Established patient complete exam of visual system | 870 | $137,709 | $103 |
| Injection of drug into eye | 343 | $137,008 | $89 |
| Imaging of retina | 1,001 | $84,409 | $36 |
| Established patient problem focused exam of visual system | 317 | $78,274 | $77 |
| New patient visit (45+ min) | 339 | $44,576 | $131 |
| Injection, bevacizumab, 10 mg | 208 | $42,025 | None |
| Photography of the retina | 590 | $30,566 | $44 |
| 2d ultrasound scan of eye tissue and structures | 366 | $30,446 | $56 |
| Long return visit (40+ min) | 173 | $20,080 | $116 |
| Removal of membrane of retina | 11 | $12,264 | $1,115 |
| Destruction of eye fluid (vitreous) between lens and retina and all of retina using a laser | 12 | $12,143 | $867 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 137 | $11,987 | $87 |
| Removal of eye fluid (vitreous) between lens and retina | 12 | $11,417 | $878 |
| Photocoagulation treatment to prevent detachment of retina | 22 | $11,331 | $472 |
| Examination of eye by ophthalmoscope with retinal drawing | 205 | $10,001 | $23 |
| Removal of eye fluid | 68 | $9,986 | $109 |
| Compounded drug, not otherwise classified | 88 | $8,033 | None |
| Examination of eye by ophthalmoscope with retinal drawing | 169 | $7,892 | $25 |
| Destruction of growth of retina using a laser | 13 | $7,132 | $475 |
| Return visit (30+ min) | 35 | $3,296 | $94 |
| Injection of drug or substance into membrane covering eyeball | 14 | $1,022 | $68 |
| Imaging of optic nerve | 16 | $459 | $29 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 23 | $142 | None |
2018: 22 services
| Injection, aflibercept, 1 mg | 70 | $514,388 | None |
| Established patient complete exam of visual system | 983 | $166,493 | $100 |
| Injection, ranibizumab, 0.1 mg | 29 | $141,532 | None |
| Injection of drug into eye | 278 | $113,597 | $89 |
| Imaging of retina | 938 | $74,311 | $35 |
| Established patient problem focused exam of visual system | 263 | $62,530 | $74 |
| Injection, bevacizumab, 10 mg | 205 | $49,960 | None |
| New patient visit (45+ min) | 293 | $38,172 | $130 |
| 2d ultrasound scan of eye tissue and structures | 308 | $35,173 | $66 |
| Photography of the retina | 533 | $34,014 | $50 |
| Destruction of eye fluid (vitreous) between lens and retina and all of retina using a laser | 13 | $14,953 | $997 |
| Examination of eye by ophthalmoscope with retinal drawing | 308 | $14,385 | $23 |
| Removal of membrane of retina | 13 | $13,729 | $1,056 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 129 | $10,409 | $78 |
| Destruction of growth of retina using a laser | 18 | $10,342 | $470 |
| Examination of eye by ophthalmoscope with retinal drawing | 170 | $7,407 | $24 |
| Destruction of leaking blood vessels of retina using laser | 11 | $3,951 | $282 |
| Long return visit (40+ min) | 20 | $2,502 | $125 |
| Removal of eye fluid | 11 | $1,538 | $103 |
| Injection of drug or substance into membrane covering eyeball | 12 | $1,265 | $84 |
| Imaging of optic nerve | 17 | $540 | $30 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 22 | $188 | None |
2017: 22 services
| Injection, aflibercept, 1 mg | 55 | $303,577 | None |
| Established patient complete exam of visual system | 941 | $167,735 | $97 |
| Injection of drug into eye | 279 | $109,383 | $88 |
| Imaging of retina | 855 | $70,560 | $34 |
| Injection, bevacizumab, 10 mg | 239 | $59,755 | None |
| 2d ultrasound scan of eye tissue and structures | 275 | $37,902 | $80 |
| Photography of the retina | 449 | $34,455 | $58 |
| New patient visit (45+ min) | 264 | $33,757 | $128 |
| Established patient problem focused exam of visual system | 189 | $24,017 | $76 |
| Removal of membrane of retina with removal of internal limiting membrane of retina | 12 | $14,018 | $1,078 |
| Return visit (30+ min) | 116 | $13,801 | $77 |
| Examination of eye by ophthalmoscope with retinal drawing | 313 | $13,598 | $21 |
| Destruction of growth of retina using a laser | 20 | $11,812 | $454 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 138 | $10,081 | $69 |
| Photocoagulation treatment to prevent detachment of retina | 17 | $7,779 | $458 |
| Examination of eye by ophthalmoscope with retinal drawing | 174 | $7,425 | $23 |
| Destruction of leaking blood vessels of retina using laser | 11 | $4,316 | $308 |
| Removal of eye fluid | 28 | $3,586 | $102 |
| Long return visit (40+ min) | 33 | $3,193 | $97 |
| Short return visit (20+ min) | 21 | $1,326 | $60 |
| Imaging of optic nerve | 20 | $695 | $30 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 43 | $358 | None |
2016: 22 services
| Injection, aflibercept, 1 mg | 28 | $194,734 | None |
| Established patient complete exam of visual system | 840 | $172,278 | $96 |
| Injection of drug into eye | 258 | $96,270 | $88 |
| Imaging of retina | 790 | $71,886 | $38 |
| Injection, bevacizumab, 10 mg | 228 | $54,921 | None |
| 2d ultrasound scan of eye tissue and structures | 285 | $42,188 | $81 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 202 | $38,582 | $93 |
| Photography of the retina | 431 | $35,926 | $67 |
| New patient visit (45+ min) | 262 | $33,859 | $129 |
| Examination of eye by ophthalmoscope with retinal drawing | 426 | $20,488 | $21 |
| Removal of membrane of retina | 15 | $16,074 | $1,072 |
| Examination of eye by ophthalmoscope with retinal drawing | 326 | $14,916 | $23 |
| Return visit (30+ min) | 107 | $14,160 | $91 |
| Destruction of growth of retina using a laser | 24 | $13,920 | $449 |
| Destruction of eye fluid (vitreous) between lens and retina and all of retina using a laser | 13 | $12,669 | $975 |
| Established patient problem focused exam of visual system | 68 | $6,570 | $71 |
| Removal of eye fluid | 36 | $6,564 | $108 |
| Long return visit (40+ min) | 43 | $4,161 | $95 |
| New patient visit (60+ min) | 18 | $2,770 | $154 |
| Injection of drug or substance into membrane covering eyeball | 12 | $1,111 | $79 |
| Short return visit (20+ min) | 11 | $660 | $55 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 31 | $319 | None |
2015: 24 services
| Established patient complete exam of visual system | 819 | $177,555 | $96 |
| Injection, aflibercept, 1 mg | 30 | $133,756 | None |
| Imaging of retina | 790 | $71,732 | $38 |
| Removal of eye fluid | 220 | $70,453 | $103 |
| Injection of drug into eye | 243 | $46,012 | $60 |
| Injection, bevacizumab, 10 mg | 225 | $45,285 | None |
| Exam of retinal blood vessels using a special camera after injection of a dye | 181 | $34,918 | $91 |
| Destruction of growth of retina using a laser | 51 | $34,052 | $431 |
| 2d ultrasound scan of eye tissue and structures | 250 | $31,663 | $81 |
| New patient visit (45+ min) | 199 | $25,790 | $130 |
| Photography of the retina | 299 | $22,660 | $66 |
| Established patient problem focused exam of visual system | 134 | $14,398 | $67 |
| Examination of eye by ophthalmoscope with retinal drawing | 289 | $14,223 | $22 |
| Destruction of leaking blood vessels of retina using laser | 13 | $14,132 | $883 |
| Removal of membrane of retina | 12 | $13,917 | $1,071 |
| Examination of eye by ophthalmoscope with retinal drawing | 280 | $12,469 | $23 |
| Photocoagulation treatment to prevent detachment of retina | 14 | $6,999 | $437 |
| Long return visit (40+ min) | 40 | $4,684 | $117 |
| New patient visit (60+ min) | 25 | $4,277 | $171 |
| New patient complete exam of visual system | 21 | $2,457 | $117 |
| Injection of drug or substance into membrane covering eyeball | 11 | $1,146 | $82 |
| Return visit (30+ min) | 13 | $1,142 | $88 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 45 | $435 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 61 | $8 | None |
2014: 23 services
| Injection, aflibercept, 1 mg | 54 | $285,339 | None |
| Established patient complete exam of visual system | 895 | $200,974 | $98 |
| Removal of eye fluid | 258 | $101,437 | $107 |
| Imaging of retina | 890 | $81,891 | $39 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 251 | $50,102 | $93 |
| Injection of drug into eye | 259 | $46,362 | $47 |
| Injection, bevacizumab, 10 mg | 215 | $37,193 | None |
| Injection, ranibizumab, 0.1 mg | 14 | $36,583 | None |
| Destruction of growth of retina using a laser | 57 | $36,443 | $456 |
| 2d ultrasound scan of eye tissue and structures | 243 | $33,365 | $81 |
| New patient visit (45+ min) | 245 | $31,404 | $128 |
| Examination of eye by ophthalmoscope with retinal drawing | 583 | $27,163 | $24 |
| Destruction of leaking blood vessels of retina using laser | 19 | $20,703 | $828 |
| Photography of the retina | 244 | $18,406 | $64 |
| Repair of detached retina with drainage and removal of eye fluid between lens and retina | 11 | $16,327 | $1,484 |
| Examination of eye by ophthalmoscope with retinal drawing | 227 | $12,022 | $21 |
| Established patient problem focused exam of visual system | 119 | $11,758 | $75 |
| Photocoagulation treatment to prevent detachment of retina | 13 | $7,145 | $447 |
| Injection of drug or substance into membrane covering eyeball | 65 | $4,958 | $51 |
| New patient visit (60+ min) | 15 | $2,678 | $179 |
| Long return visit (40+ min) | 24 | $2,427 | $101 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 28 | $189 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 92 | $16 | None |
2013: 28 services
| Injection, aflibercept, 1 mg | 94 | $507,182 | None |
| Established patient complete exam of visual system | 909 | $225,931 | $102 |
| Removal of eye fluid | 268 | $99,198 | $104 |
| Injection, ranibizumab, 0.1 mg | 30 | $86,575 | None |
| Imaging of retina | 886 | $85,289 | $40 |
| 2d ultrasound scan of eye tissue and structures | 327 | $53,774 | $83 |
| Injection of drug into eye | 270 | $45,483 | $46 |
| Destruction of growth of retina using a laser | 59 | $44,721 | $461 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 225 | $44,010 | $95 |
| New patient visit (45+ min) | 239 | $31,133 | $130 |
| Removal of membrane of retina | 16 | $20,712 | $1,218 |
| Photography of the retina | 269 | $18,380 | $63 |
| Destruction of leaking blood vessels of retina using laser | 15 | $18,215 | $867 |
| Repair of detached retina with drainage and removal of eye fluid between lens and retina | 12 | $18,084 | $1,507 |
| Unclassified biologics | 138 | $17,733 | None |
| Destruction of eye fluid (vitreous) between lens and retina and all of retina using a laser | 13 | $17,663 | $1,359 |
| Long return visit (40+ min) | 149 | $16,788 | $111 |
| Removal of membrane of retina | 12 | $14,271 | $1,189 |
| Injection, bevacizumab, 10 mg | 125 | $13,452 | None |
| Injection of drug or substance into membrane covering eyeball | 109 | $13,182 | $45 |
| Examination of eye by ophthalmoscope with retinal drawing | 169 | $7,636 | $24 |
| Destruction of vascular growth between retina and sclera by photocoagulation | 11 | $5,338 | $445 |
| Exam of blood vessels between the white part of eye and retina using a special camera after injection of a dye | 11 | $4,089 | $195 |
| Established patient problem focused exam of visual system | 37 | $3,715 | $69 |
| New patient visit (60+ min) | 11 | $1,957 | $178 |
| Examination of eye by ophthalmoscope with retinal drawing | 42 | $1,810 | $22 |
| New patient visit (30+ min) | 11 | $1,059 | $96 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 13 | $29 | None |
Medicaid work
$172,734 in 2024
Medicaid paid $172,734 for 3,140 billed services this clinician did in 2024, up to 108 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Injection, faricimab-svoa, 0.1 mg | 138 | $86,283 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 596 | $26,424 |
| Ranibizumab injection | 79 | $20,288 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 406 | $11,691 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 808 | $7,441 |
| Injection, bevacizumab, 10 mg | 241 | $6,747 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 356 | $5,202 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 218 | $3,073 |
| Return visit (30+ min) | 39 | $2,714 |
| OPH US DX B-SCAN | 233 | $2,048 |
| New patient visit (45+ min) | 26 | $822 |
| 2024 | 3,140 | 11 | 108 | $172,734 |
| 2023 | 3,677 | 11 | 106 | $141,475 |
| 2022 | 3,091 | 10 | 74 | $82,679 |
| 2021 | 2,879 | 9 | 86 | $89,359 |
| 2020 | 2,381 | 9 | 82 | $66,465 |
| 2019 | 3,271 | 12 | 88 | $81,670 |
| 2018 | 3,401 | 20 | 66 | $74,813 |
See the largest Medicaid services in earlier years
2023
| Ranibizumab injection | 211 | $54,263 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 656 | $26,144 |
| Aflibercept injection | 29 | $11,777 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 550 | $10,525 |
| Injection, faricimab-svoa, 0.1 mg | 26 | $8,753 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 445 | $8,399 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 856 | $5,760 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 374 | $5,634 |
| New patient visit (45+ min) | 79 | $4,022 |
| Injection, bevacizumab, 10 mg | 179 | $3,967 |
| OPH US DX B-SCAN | 272 | $2,231 |
2022
| Intravitreal injection of a pharmacologic agent (separate procedure) | 573 | $27,485 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 429 | $11,588 |
| Aflibercept injection | 26 | $9,259 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 450 | $7,866 |
| Injection, bevacizumab, 10 mg | 269 | $7,292 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 722 | $5,747 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 295 | $4,531 |
| New patient visit (45+ min) | 81 | $3,646 |
| Ranibizumab injection | 15 | $3,535 |
| OPH US DX B-SCAN | 231 | $1,729 |
2021
| Intravitreal injection of a pharmacologic agent (separate procedure) | 554 | $29,582 |
| Aflibercept injection | 84 | $24,162 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 403 | $8,851 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 423 | $6,780 |
| Injection, bevacizumab, 10 mg | 242 | $6,211 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 722 | $4,560 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 209 | $3,729 |
| New patient visit (45+ min) | 57 | $2,952 |
| OPH US DX B-SCAN | 185 | $2,531 |
2020
| Intravitreal injection of a pharmacologic agent (separate procedure) | 467 | $21,655 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 288 | $9,630 |
| Injection, bevacizumab, 10 mg | 232 | $8,232 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 381 | $6,269 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 595 | $5,882 |
| Aflibercept injection | 15 | $5,633 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 204 | $4,277 |
| OPH US DX B-SCAN | 155 | $2,800 |
| New patient visit (45+ min) | 44 | $2,086 |
2019
| Intravitreal injection of a pharmacologic agent (separate procedure) | 515 | $27,271 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 358 | $11,179 |
| Injection, bevacizumab, 10 mg | 366 | $9,967 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 542 | $9,170 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 837 | $7,731 |
| New patient visit (45+ min) | 89 | $6,739 |
| OPH US DX B-SCAN | 243 | $5,054 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 237 | $4,408 |
| Ophthalmoscopy, extended, with retinal drawing (eg, for retinal detachment, melanoma), with interpretation and report; subsequent | 25 | $152 |
| TOBACCO NON-USER | 20 | $0 |
| Patient not eligible due to active diagnosis of hypertension | 18 | $0 |
| Patient screened for tobacco use and identified as a tobacco non-user | 21 | $0 |
2018
| Intravitreal injection of a pharmacologic agent (separate procedure) | 388 | $28,727 |
| Injection, bevacizumab, 10 mg | 380 | $10,978 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 279 | $10,368 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 497 | $7,572 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 669 | $6,270 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 203 | $4,351 |
| OPH US DX B-SCAN | 179 | $3,220 |
| New patient visit (45+ min) | 41 | $3,056 |
| Ophthalmoscopy, extended, with retinal drawing (eg, for retinal detachment, melanoma), with interpretation and report; subsequent | 80 | $272 |
| TOBACCO NON-USER | 177 | $0 |
| DILATED MACUL EXAM DONE | 15 | $0 |
| Dilated retinal eye exam with interpretation by an ophthalmologist or optometrist documented and reviewed; with evidence of retinopathy (DM) | 69 | $0 |
Drugs they prescribed that Part D paid
$27,099
Pharmacies billed $27,099 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 591) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
364 generic and 227 brand-name prescriptions · $27,099 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Prednisolone Acetate | 118 | $5,838 | $49 |
| Prolensa | 16 | $5,365 | $335 |
| Tobramycin-Dexamethasone | 114 | $4,023 | $35 |
| Brimonidine | 134 | $1,166 | $9 |
| Dorzolamide-Timolol | 59 | $981 | $17 |
See all 8 drugs
| Prednisolone Acetate | 118 | $5,838 | $49 |
| Prolensa | 16 | $5,365 | $335 |
| Tobramycin-Dexamethasone | 114 | $4,023 | $35 |
| Brimonidine | 134 | $1,166 | $9 |
| Dorzolamide-Timolol | 59 | $981 | $17 |
| Latanoprost | 51 | $802 | $16 |
| Atropine Sulfate | 13 | $679 | $52 |
| Neomycin-Polymyxin-Dexameth | 25 | $358 | $14 |
Year by year
| 2024 | 591 | 185 | 0% (0) | 38% | $27,099 |
| 2023 | 527 | 173 | 0% (0) | 41% | $38,989 |
| 2022 | 461 | 138 | None | 39% | $40,306 |
| 2021 | 470 | 138 | None | 41% | $43,434 |
| 2020 | 618 | 161 | None | 53% | $71,455 |
| 2019 | 625 | 163 | None | 50% | $66,197 |
| 2018 | 661 | 153 | None | 57% | $71,460 |
| 2017 | 625 | 161 | None | 47% | $51,785 |
| 2016 | 703 | 158 | None | 50% | $64,629 |
| 2015 | 789 | 179 | None | 56% | $85,218 |
| 2014 | 681 | 156 | None | 53% | $63,481 |
| 2013 | 557 | 151 | None | 57% | $48,102 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 6 drugs
| Tobramycin-Dexamethasone | 97 | $6,399 | $66 |
| Prolensa | 16 | $5,808 | $363 |
| Prednisolone Acetate | 88 | $5,453 | $62 |
| Brimonidine | 137 | $4,427 | $32 |
| Latanoprost | 60 | $1,552 | $26 |
| Dorzolamide-Timolol | 50 | $1,245 | $25 |
2022: 7 drugs
| Prednisolone Acetate | 80 | $5,545 | $69 |
| Prolensa | 14 | $4,629 | $331 |
| Tobramycin-Dexamethasone | 54 | $4,140 | $77 |
| Brimonidine | 122 | $3,748 | $31 |
| Combigan | 15 | $3,742 | $249 |
| Dorzolamide-Timolol | 60 | $1,716 | $29 |
| Latanoprost | 52 | $1,255 | $24 |
2021: 8 drugs
| Restasis | 13 | $12,024 | $925 |
| Combigan | 27 | $6,874 | $255 |
| Tobramycin-Dexamethasone | 61 | $4,980 | $82 |
| Prednisolone Acetate | 73 | $4,760 | $65 |
| Brimonidine | 105 | $4,117 | $39 |
| Dorzolamide-Timolol | 45 | $1,894 | $42 |
| Latanoprost | 76 | $1,851 | $24 |
| Neomycin-Polymyxin-Dexameth | 11 | $169 | $15 |
2020: 10 drugs
| Restasis | 16 | $18,151 | $1,134 |
| Combigan | 27 | $8,043 | $298 |
| Prednisolone Acetate | 103 | $6,108 | $59 |
| Brimonidine | 105 | $5,229 | $50 |
| Tobramycin-Dexamethasone | 58 | $4,968 | $86 |
| Prolensa | 15 | $4,333 | $289 |
| Travatan Z | 17 | $3,594 | $211 |
| Dorzolamide-Timolol | 56 | $2,392 | $43 |
| Latanoprost | 113 | $1,911 | $17 |
| Timolol Maleate | 12 | $153 | $13 |
2019: 11 drugs
| Restasis | 17 | $15,140 | $891 |
| Tobramycin-Dexamethasone | 104 | $8,796 | $85 |
| Brimonidine | 95 | $8,347 | $88 |
| Combigan | 24 | $7,031 | $293 |
| Prednisolone Acetate | 76 | $4,538 | $60 |
| Durezol | 18 | $3,687 | $205 |
| Dorzolamide-Timolol | 74 | $3,401 | $46 |
| Alphagan P | 18 | $3,257 | $181 |
| Latanoprost | 90 | $1,758 | $20 |
| Olopatadine | 13 | $530 | $41 |
| Timolol Maleate | 27 | $301 | $11 |
2018: 13 drugs
| Restasis | 21 | $14,854 | $707 |
| Brimonidine | 128 | $10,947 | $86 |
| Tobramycin-Dexamethasone | 96 | $7,831 | $82 |
| Prednisolone Acetate | 84 | $5,437 | $65 |
| Combigan | 19 | $5,046 | $266 |
| Acetazolamide | 12 | $2,808 | $234 |
| Alphagan P | 16 | $2,464 | $154 |
| Latanoprost | 74 | $1,651 | $22 |
| Dorzolamide-Timolol | 49 | $1,266 | $26 |
| Ketorolac Tromethamine | 16 | $948 | $59 |
| Olopatadine | 17 | $741 | $44 |
| Timolol Maleate | 32 | $401 | $13 |
| Neomycin-Polymyxin-Dexameth | 18 | $252 | $14 |
2017: 13 drugs
| Restasis | 26 | $14,895 | $573 |
| Tobramycin-Dexamethasone | 68 | $7,093 | $104 |
| Prednisolone Acetate | 79 | $5,465 | $69 |
| Brimonidine | 82 | $3,589 | $44 |
| Alphagan P | 13 | $3,012 | $232 |
| Travatan Z | 13 | $2,393 | $184 |
| Combigan | 12 | $2,285 | $190 |
| Dorzolamide-Timolol | 102 | $2,154 | $21 |
| Latanoprost | 100 | $1,716 | $17 |
| Ketorolac Tromethamine | 25 | $1,385 | $55 |
| Olopatadine | 15 | $721 | $48 |
| Neomycin-Polymyxin-Dexameth | 26 | $299 | $11 |
| Timolol Maleate | 12 | $155 | $13 |
2016: 17 drugs
| Restasis | 21 | $10,891 | $519 |
| Tobramycin-Dexamethasone | 69 | $8,903 | $129 |
| Alphagan P | 48 | $8,805 | $183 |
| Brimonidine | 87 | $7,150 | $82 |
| Prednisolone Acetate | 58 | $3,827 | $66 |
| Lotemax | 17 | $3,603 | $212 |
| Prolensa | 15 | $3,138 | $209 |
| Pataday | 19 | $3,087 | $162 |
| Dorzolamide-Timolol | 123 | $2,599 | $21 |
| Combigan | 14 | $2,563 | $183 |
| Travatan Z | 11 | $2,454 | $223 |
| Latanoprost | 83 | $1,194 | $14 |
| Atropine Sulfate | 19 | $960 | $51 |
| Ketorolac Tromethamine | 22 | $846 | $38 |
| Neomycin-Polymyxin-Dexameth | 21 | $386 | $18 |
| Olopatadine | 15 | $336 | $22 |
| Timolol Maleate | 15 | $88 | $6 |
2015: 17 drugs
| Restasis | 26 | $12,508 | $481 |
| Tobramycin-Dexamethasone | 84 | $11,246 | $134 |
| Brimonidine | 105 | $9,884 | $94 |
| Prolensa | 26 | $7,372 | $284 |
| Patanol | 28 | $6,760 | $241 |
| Alphagan P | 36 | $6,624 | $184 |
| Prednisolone Acetate | 77 | $5,123 | $67 |
| Lotemax | 25 | $4,931 | $197 |
| Pataday | 23 | $3,520 | $153 |
| Combigan | 15 | $3,449 | $230 |
| Dorzolamide-Timolol | 91 | $1,779 | $20 |
| Acetazolamide | 11 | $1,431 | $130 |
| Latanoprost | 91 | $1,222 | $13 |
| Atropine Sulfate | 31 | $783 | $25 |
| Ketorolac Tromethamine | 19 | $720 | $38 |
| Neomycin-Polymyxin-Dexameth | 21 | $469 | $22 |
| Timolol Maleate | 14 | $192 | $14 |
2014: 17 drugs
| Tobramycin-Dexamethasone | 81 | $11,361 | $140 |
| Brimonidine | 118 | $11,202 | $95 |
| Pataday | 42 | $6,108 | $145 |
| Prednisolone Acetate | 62 | $4,411 | $71 |
| Restasis | 12 | $3,670 | $306 |
| Prolensa | 16 | $3,379 | $211 |
| Patanol | 17 | $2,860 | $168 |
| Alphagan P | 16 | $2,794 | $175 |
| Combigan | 19 | $2,324 | $122 |
| Bromfenac | 19 | $1,949 | $103 |
| Travatan Z | 11 | $1,296 | $118 |
| Dorzolamide-Timolol | 40 | $1,008 | $25 |
| Latanoprost | 59 | $886 | $15 |
| Ketorolac Tromethamine | 23 | $746 | $32 |
| Atropine Sulfate | 28 | $575 | $21 |
| Timolol Maleate | 30 | $425 | $14 |
| Neomycin-Polymyxin-Dexameth | 13 | $222 | $17 |
2013: 14 drugs
| Tobramycin-Dexamethasone | 81 | $11,997 | $148 |
| Pataday | 36 | $4,824 | $134 |
| Bromday | 17 | $3,608 | $212 |
| Alphagan P | 30 | $3,051 | $102 |
| Brimonidine | 37 | $2,832 | $77 |
| Patanol | 18 | $2,473 | $137 |
| Prednisolone Acetate | 75 | $2,377 | $32 |
| Combigan | 23 | $2,234 | $97 |
| Bromfenac | 11 | $1,327 | $121 |
| Travatan Z | 11 | $1,112 | $101 |
| Latanoprost | 51 | $902 | $18 |
| Dorzolamide-Timolol | 26 | $843 | $32 |
| Timolol Maleate | 29 | $356 | $12 |
| Atropine Sulfate | 15 | $237 | $16 |
Money from drug and device companies
$302 in 2025
| 2025 | 2 | 3 | None | $302 |
| 2024 | 4 | 6 | None | $559 |
| 2023 | 5 | 11 | None | $381 |
| 2022 | 3 | 3 | None | $127 |
| 2021 | 2 | 3 | None | $67 |
| 2020 | 4 | 6 | None | $116 |
| 2019 | 5 | 9 | None | $195 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Regeneron Pharmaceuticals | Eylea Hd | $281 | 2 payments
|
| Astellas Pharma US | Izervay | $21 | 1 payment
|
See all 3 published payments
| Regeneron Pharmaceuticals | Meals · 2025-12-04 | Eylea Hd | $131 |
| Astellas Pharma US | Meals · 2025-11-05 | Izervay | $21 |
| Regeneron Pharmaceuticals | Meals · 2025-04-16 | None | $150 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $559
| Astellas Pharma US | Izervay | $267 | 3 payments
|
| Mallinckrodt Hospital Products | Acthar | $140 | 1 payment
|
| EyePoint Pharmaceuticals US | None | $125 | 1 payment
|
| Apellis Pharmaceuticals | Syfovre | $27 | 1 payment
|
2023: $381
| Astellas Pharma US | None | $167 | 4 payments
|
| Genentech USA | Vabysmo | $100 | 3 payments
|
| Apellis Pharmaceuticals | Syfovre | $52 | 2 payments
|
| Regeneron Healthcare Solutions | Eylea Hd | $32 | 1 payment
|
| AbbVie | Ozurdex | $30 | 1 payment
|
2022: $127
| Genentech | Lucentis | $72 | 1 payment
|
| Regeneron Healthcare Solutions | Eylea | $34 | 1 payment
|
| Genentech USA | Vabysmo | $22 | 1 payment
|
2021: $67
| Genentech USA | Lucentis | $46 | 2 payments
|
| Regeneron Healthcare Solutions | Eylea | $21 | 1 payment
|
2020: $116
| Alimera Sciences | Iluvien | $46 | 2 payments
|
| Optos | P200dtx | $39 | 2 payments
|
| Novartis Pharmaceuticals | Beovu | $19 | 1 payment
|
| Regeneron Healthcare Solutions | Eylea | $13 | 1 payment
|
2019: $195
| Genentech USA | Lucentis | $74 | 3 payments
|
| Novartis Pharmaceuticals | Beovu | $40 | 2 payments
|
| Alimera Sciences | Iluvien | $33 | 2 payments
|
| Regeneron Healthcare Solutions | Eylea | $28 | 1 payment
|
| Optos | P200dtx | $20 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 100.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1699763748
- Licence
- CA G83824California G83824: Current · expires 2027-06-30
- Trained
- New York University Medical College - Nlg, 1993
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00G8388240
- Taxonomy
- Federal specialty code 207W00000X (207W00000X)
- Mailing address
- 3395 S Bascom Ave Ste 140, Campbell, CA, 95008
- NPI first listed
- 2005-10-12
- NPI last updated
- 2025-11-20
- NPI record certified
- 2025-11-20
This is when the NPI record was last certified, not a medical board exam.